Real-world comparison of chemoimmunotherapy and chemotherapy alone in elderly patients (≥75 years) with extensive-stage small cell lung Cancer.

Authors

Xue Dong, Wenjie Chen, Ruyue Li, Xiujing Yao, Yintao Li

Published in

Future oncology (London, England). Pages 1-9. Jun 27, 2026. Epub Jun 27, 2026.

Abstract

Given the underrepresentation of adults aged ≥75 years with extensive-stage small-cell lung cancer (ES-SCLC) in clinical trials, we compared first-line chemoimmunotherapy versus chemotherapy in this population.
This retrospective study enrolled 88 patients aged ≥75 years with ES-SCLC treated with either chemotherapy alone (n = 42) or chemoimmunotherapy (n = 46). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and safety. Multivariable Cox regression and stabilized inverse probability of treatment weighting (IPTW) analyses were performed to reduce confounding.
Median OS and PFS were 14.3 (95% CI: 11.6-22.5) and 6.6 in the chemotherapy group and 16.9 (95% CI: 12.7-NA) and 7.6 months in the chemoimmunotherapy group, respectively (HR: 0.90, 95% CI: 0.51-1.58, p = 0.71; HR: 0.75, 95% CI: 0.43-1.29, p = 0.30, respectively). Multivariate analysis identified smoking status as an independent predictor of OS (HR: 2.10, 95% CI: 1.01-4.38, p = 0.048).
Among patients aged ≥75 years with ES-SCLC, chemoimmunotherapy was associated with numerically longer OS compared with chemotherapy alone, although this difference did not reach statistical significance.

PMID:
42363803
Bibliographic data and abstract were imported from PubMed on 27 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.